Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| ARROWHEAD RESEARCH (NASDAQ: ARWR) | Delayed: 57.27 -1.57 (2.67%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $58.84 | 52 Week High | $8.22 | |||
| Open | $58.06 | 52 Week Low | $3.07 | |||
| Day High | $59.90 | P/E | N/A | |||
| Day Low | $56.97 | EPS | $-1.30 | |||
| Volume | 303,312 | |||||
